Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies

A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and MTD of GRN163L in Patients With Refractory or Relapsed Solid Tumor Malignancies

The purpose of this study is to determine the safety and the maximum tolerated dose of GRN163L administration in treating patients with refractory or relapsed solid tumor malignancies.

GRN163L is a telomerase template antagonist with in vitro and in vivo activity in a variety of tumor model systems. Telomerase is an enzyme that is active primarily in tumor cells and is crucial for the indefinite growth of tumor cells. Inhibition of telomerase may result in antineoplastic effects.

Inclusion Criteria:

• 18 years of age or older
• Male or female
• Measurable or evaluable solid tumor malignancy
• Relapsed, refractory, locally advanced, or metastatic disease
• Disease refractory to or not amenable to standard therapy
• Karnofsky performance status 70-100%
• Life expectancy 3 months or greater

Exclusion Criteria:

• Pregnant or lactating women
• Primary central nervous system(CNS) malignancy or active CNS metastases
• Hematologic malignancy
• Chemotherapy within 4 weeks prior to study
• Mitomycin C, nitrosoureas within 6 weeks prior to study
• High dose chemotherapy with stem cell support within 6 months prior to study
• Signal transduction inhibitors, monoclonal antibodies, etc. within 4 weeks prior to study
• Systemic hormonal therapy within 4 weeks prior to study
• Anticoagulant therapy, antiplatelet therapy within 2 weeks prior to study
• Radiotherapy within 4 weeks prior to study
• Significant cardiovascular disease
• Serious/active infection
• Major surgical procedures within 2 weeks